Undisclosed eIF4Ai ADC / Zymeworks - LARVOL DELTA

Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads (GlobeNewswire) - "Zymeworks presents new preclinical data at AACR 2026....Zymeworks presented a novel class of eIF4A inhibitor payloads designed to inhibit mRNA translation and enable a new mechanism for ADC therapies. Key findings include: Over 40 novel eIF4A inhibitor payloads synthesized spanning a range of potency and hydrophilicity....Demonstrated robust anti-tumor activity across multiple targets including HER2, TROP2, EGFR, Ly6E, and PTK7."

Preclinical • Solid Tumor